Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T00158
|
|||||
Target Name |
HUMAN glycosylation of host receptor (GHR)
|
|||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Malaria [ICD-11: 1F40-1F45] |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Drugs in Phase 3 Trial | [+] 6 | + | ||||
1 | Hydroxychloroquine | Drug Info | Approved | Malaria | [2] | |
2 | Azithromycin + hydroxychloroquine | Drug Info | Phase 3 | Coronavirus Disease 2019 (COVID-19) | [3] | |
3 | Chloroquine | Drug Info | Phase 3 | Coronavirus Disease 2019 (COVID-19) | [4] | |
4 | Darunavir + ritonavir + favipiravir + hydroxychloroquine | Drug Info | Phase 3 | Coronavirus Disease 2019 (COVID-19) | [5] | |
5 | Darunavir + ritonavir + oseltamivir + hydroxychloroquine | Drug Info | Phase 3 | Coronavirus Disease 2019 (COVID-19) | [5] | |
6 | Oseltamivir + hydroxychloroquine | Drug Info | Phase 3 | Coronavirus Disease 2019 (COVID-19) | [5] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Inhibitor | [+] 6 Inhibitor drugs | + | ||||
1 | Azithromycin + hydroxychloroquine | Drug Info | [1], [6] | |||
2 | Chloroquine | Drug Info | [1], [6] | |||
3 | Darunavir + ritonavir + favipiravir + hydroxychloroquine | Drug Info | [1], [6] | |||
4 | Darunavir + ritonavir + oseltamivir + hydroxychloroquine | Drug Info | [1], [6] | |||
5 | Hydroxychloroquine | Drug Info | [1], [6] | |||
6 | Oseltamivir + hydroxychloroquine | Drug Info | [1], [6] |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. | |||||
REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
REF 3 | ClinicalTrials.gov (NCT04321278) Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). U.S. National Institutes of Health. | |||||
REF 4 | ClinicalTrials.gov (NCT04360759) Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19. U.S. National Institutes of Health. | |||||
REF 5 | ClinicalTrials.gov (NCT04303299) Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial | |||||
REF 6 | Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat Nanotechnol. 2020 Apr;15(4):247-249. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.